Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in EuropeInitial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in EuropeInitial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia
Profusa Invests Additional $1 Million in Digital Treasury AssetsBERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces its second $1 million investment in digital treasury assets to hedge against macroeconomic uncertainties, in line with the Company’s treasury management strategy.
